FDA panel recommends change to label of Abilify - Related Stories - AAP SmartBrief
Links shared publicly online about this topic.
- 1,539total visits
FDA panel recommends change to label of Abilify - Related Stories - AAP SmartBrief
An FDA panel unanimously concluded that the label of Bristol-Myers Squibb's antipsychotic Abilify for use in children lacks information on the risk of excessive weight gain. The panel advised Bristol-Myers to keep monitoring pediatric use of the drug and move data on its metabolic effect on children
View full resource at smartbrief.com
Tags: Bipolar Disorder Medication, Schizophrenia Medication, Antipsychotic Medication, Children's Health, FDA, American Academy of Pediatrics, Abilify, Bristol-Myers Squibb
Most Recently Shared on December 11, 2009 at 6:07 am By:
FDA panel recommends change to label of Abilify http://sbne.ws/r/3qaF
Advertisement
